We examined the effect of resveratrol (3, 4', 5-trihydroxy stilbene), a phenolic compound found in the skins of most grapes, on blood pressure and bone loss in ovariec tomized (OVX), stroke-prone spontaneously hypertensive rats (SHRSP). Nineteen-week-old female SHRSP were divided into a sham-ovariectomized (sham) group fed a control diet and two OVX groups fed either a control diet (OVX-Cont) or a diet supplemented with resveratrol (5mg/kg per d; OVX-Resv). Ovariectomy induced significant increases in systolic blood pressure (SBP). Resveratrol lowered the SBP by 15% by the third week of administration, and this effect was maintained throughout the study. Resveratrol treatment also signifi cantly enhanced endothelium-dependent vascular relaxation in response to acetylcholine (ACh) in OVX rats. Finally, femur breaking energies measured for the resveratrol-treated (OVX-Resv) group were significantly higher than those of the resveratrol-untreated (OVX -Cont) group. While no significant differences in calcium, magnesium and phosphorus con tent were found between the femurs of OVX-Cont and OVX-Resv rats, the femur hydroxy proline content in the OVX-Resv group was significantly higher than of the OVX-Cont group. We conclude that, in OVX-SHRSP, resveratrol acts by a similar mechanism to mam malian estrogens, lowering blood pressure by increasing dilatory responses to ACh . The present study also demonstrated that resveratrol was able to prevent ovariectomy-induced decreases in femoral bone strength.
Women of reproductive age are known to have a lower risk of coronary heart disease (CHD) than men (1) (2) (3) . Following loss of ovarian function, post menopausal women display an increased incidence of hypertension and CHD (4) , and this effect appears to be reversed by estrogen replacement therapy (5, 6) . Hypertension develops more rapidly and is more severe in males than in females in genetic and other hyperten sive animal models (7, 8) . Estrogen deficiency after menopause is also associated with osteoporosis, being the most common cause of age-related bone loss. A sharp decrease in ovarian estrogen production is the predominant cause of rapid bone loss during the first decade after menopause (9) . Taken together, these find ings suggest that estrogen supplementation may delay both hypertension and bone loss.
Some women are reluctant to take estrogen replace ments because of potentially increased cancer risks (10) . It would be useful to identify a natural dietary substance that minimizes both vascular diseases and bone loss attributable to loss of ovarian function in post menopausal women without significantly increasing the risk of estrogen-dependent cancers. Diets higher contractile responses (10-4M L-NAME) were ob served in tissues from the OVX-Resv group as compared to the OVX-Cont group (Fig. 4) . Femoral mechanical strength and its components Measured femoral mechanical properties (breaking load and breaking energy) are shown in Table 2 . The femoral breaking load of the OVX-Copt group was lower than that of the sham group. The OVX-Resv group had a higher femoral breaking load value than the OVX -Cont group, but the difference was not statistically sig nificant. In contrast, femoral breaking energies for the OVX-Resv group were significantly higher than those for the OVX-Cont group. Femoral Ca, Mg, P and Hyp contents are shown in Table 3 . No significant differ ences in Ca, Mg, or P were found between the OVX-Cont and OVX-Resv groups. However, total femoral Hyp in the OVX-Resv group was significantly higher than in the OVX-Copt group.
DISCUSSIONS
Recent publications have highlighted geographical differences in the prevalence of many diseases, includ ing CHD (24), breast cancer (25), osteoporosis (26) and menopausal symptoms (27) . The potential biological impact of environmental and dietary estrogens on human health has generated considerable interest (28) (29) (30) . These agents include phytoestrogens, soy bean isoflavones (31-33) and a variety of synthetic compounds, such as the isofiavone derivative 7-iso propoxy-3-phenyl-4H-l-benzopyran-4-one (ipriflavone) (34) . Chemically, many of the known phytoestrogens are flavonoids; others are coumestans (35) or resorcylic acid lactones, and an estrogenic hydroxystilbene was recently reported to occur naturally in wood (14) . The phytoestrogen resveratrol has recently been revealed to exhibit variable degrees of estrogen receptor agonism (16) . Resveratrol occurs naturally in grapes and a vari ety of medicinal plants. In plants, resveratrol functions as a phytoalexin, serving as a protective agent against fungal infections. Because of its high concentration in grape skin, significant amounts of resveratrol are pres ent in wine (14, 36) .
The risk of hypertension and stroke is lower in post menopausal women relative to men of the same age (37), but the incidence of cerebrovascular events rap idly increases in women after menopause (38) . Alkayed et al. (39) have demonstrated that female rats sustain smaller cortical and striatal infarcts after middle cere bral artery occlusion compared with age-matched Cont group after 3-wk of feeding with resveratrol, and this effect was maintained throughout the experimental period. A direct effect of estrogen on the blood vessel wall is suggested by its ability to relax isolated blood ves sels (40, 41) , and by evidence for the presence of estro gen receptor in isolated arteries and vascular cells (42) . We showed that long-term resveratrol consumption in ovariectomized SHRSP enhanced dilatory response to ACh in aortic rings relative to the OVX-Cont group. The basal release of NO from aortic rings was assessed indi rectly, initially by inducing moderately active tone and then observing the effects of L-NAME on changes in basal NO tone (22, 23) . Basal NO release from endothe lium-intact aortic rings from the OVX-Cont group de creased significanttty as compared to the sham-operated group. Resveratrol replacement therapy in the OVX group induced a more marked contractile response to L NAME than observed in the untreated OVX group. Differences in basal NO formation are thus reflected in the responses of endothelium-intact aortic rings in the presence of L-arginine analogs. The mechanism of ac tion of resveratrol in lowering blood pressure appears to be similar to that of mammalian estrogens, involving enhancement of the dilator response to ACh, possibly by basal NO release. This observation is in agreement with the findings of a previous study suggesting that the va sodilatory action of resveratrol is mediated via an NO related mechanism (19) . The present study confirms that the oral administra tion of resveratrol has the potency to attenuate ovariec tomy-induced decreases in femoral bone strength, measured as breaking load and breaking energy. Breaking load is the maximum power that is required to break bone by the three-point bending method, while breaking energy represents the integrated power re quired to make a break. It is believed that breaking load represents a momentary and maximum power, while breaking energy reflects the overall power required to make a break. Correspondingly, breaking load is consid ered to reflect both bone mineral and bone protein such as collagen, whereas breaking energy primarily reflects bone proteins (43) . It is thought that the stimulation of bone strength caused by resveratrol intake arises from an alteration of bone metabolism, and a resulting in crease in bone protein. These results are supported by recent observations of the positive effect of soybean products, both soybean milk-based diet and soybean protein, on bone strength in female rats (21, 44) . These products are known to contain the phytoestrogens daidzin and genistin. A separate in-vitro experiment showed that genistein inhibits parathormone-stimu lated bone resorption and promotes increased alkaline phosphatase activity in rats (45) . In a previous study, we demonstrated that resveratrol stimulates prolifera tion and differentiation in osteoblastic MC3T3-E1 cells, accompanied by increases in alkaline phosphatase and collagen synthesis activity (46) . Previous studies per formed in rats and humans showed that estrogen or phytoestrogen administration inhibits increases in a urinary bone resorption marker (47-49). We have also determined changes in the urinary bone resorption markers pyridinoline and deoxypyridinoline, but the dif ferences were not statistically significant (data not shown). In the present study, although the mechanism of action is not clear, resveratrol-induced increases in bone strength in OVX-SHRSP appeared to be due to the stimulation of bone formation.
To our knowledge, this is the first report showing that resveratrol modifies blood pressure and improves bone metabolism in vivo. The results predict that dietary resveratrol could contribute to the prevention of post menopausal hypertension and osteoporosis.
